Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | UNK | — |
extra dose of Menveo; Wrong vaccine administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 12-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Co-suspect products included HPV 16-18 (HPV vaccine) for prophylaxis. Previously administered products included Menveo (received first dose on 04-DEC-2024). On 28-JUL-2025, the patient received the 2nd dose of Menveo. On an unknown date, the patient received HPV vaccine. On 28-JUL-2025, an unknown time after receiving Menveo and not applicable after receiving HPV vaccine, the patient experienced extra dose administered (Verbatim: extra dose of Menveo) and wrong vaccine administered (Verbatim: Wrong vaccine administered). The outcome of the extra dose administered and wrong vaccine administered were not applicable. Additional Information: GSK Receipt Date: 15-AUG-2025 The reporter reported that the patient received his next one early, he was supposed to get HPV shot and had second dose of Menveo (1 vial) by accident, which led to wrong vaccine administered and extra dose administered. Vaccine administration facility was the same as primary reporter.